BioSpace News Archive

Maravai LifeSciences, Inc., a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the months of November and December.

LAVA Therapeutics N.V., a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present at the Jefferies London Healthcare Conference.

Eledon Pharmaceuticals, Inc., announced that it plans to release financial results for the third quarter ended September 30, 2022 on Monday, November 14, after the close of trading.

MacroGenics, Inc. provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2022.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, reported business highlights and financial results for the third quarter ended September 30, 2022.

Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2022, and provided business highlights.

Design Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, highlighted recent progress and anticipated upcoming milestones across its clinical and research-stage pipeline of novel GeneTAC™ small molecules and reported third quarter 2022 financial results.

Eargo, Inc., a medical device company on a mission to improve hearing health, reported its financial results for the third quarter ended September 30, 2022.

DICE Therapeutics, Inc. announced that management will present at the following investor conferences.

Capricor Therapeutics will release its financial results for the third quarter ended September 30, 2022, after the market close on Thursday, November 10, 2022.